DiaSorin S.p.A. (OTCMKTS:DSRLF) has been given an average recommendation of “Hold” by the six research firms that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a sell recommendation, one has given a hold recommendation and one has given a buy recommendation to the company.
A number of equities research analysts have commented on DSRLF shares. Zacks Investment Research lowered shares of DiaSorin from a “hold” rating to a “strong sell” rating in a report on Thursday, May 20th. Morgan Stanley lowered shares of DiaSorin from an “equal weight” rating to an “underweight” rating in a research note on Thursday, March 18th. Finally, Berenberg Bank reaffirmed a “hold” rating on shares of DiaSorin in a research note on Wednesday, March 24th.
OTCMKTS:DSRLF remained flat at $$181.00 during mid-day trading on Thursday. DiaSorin has a 52-week low of $0.00 and a 52-week high of $232.00. The company’s fifty day moving average price is $174.52.
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity.
Recommended Story: How mutual funds make money
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.